Evidence map›Paper›PMID 32810190›Full record

ArticlePloS one2020

HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis.

Munenori Oyama, Yuko Ohnuki, Michio Inoue, Akinori Uruha, Satoshi Yamashita, Sachiko Yutani, Jantima Tanboon, Jin Nakahara, Shingo Suzuki, Takashi Shiina and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. HLA Genetics for the Human Diseases.Advances in experimental medicine and biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Munenori OyamaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Yuko OhnukiDepartment of Medial Ethics, Tokai University School of Medicine, Kanagawa, Japan.
Michio InoueDepartment of Neuromuscular Research, National Institute of Neuroscience, and Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
Akinori UruhaDepartment of Neuropathology, Charité-Universitätsmedizin, Berlin, Germany.ORCID 0000-0002-4758-183X
Satoshi YamashitaDepertment of Neurology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-9315-3492
Sachiko YutaniDepartment of Neurology, Tokai University School of Medicine, Isehara-shi, Kanagawa, Japan.
Jantima TanboonDepartment of Neuromuscular Research, National Institute of Neuroscience, and Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
Jin NakaharaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Shingo SuzukiDepartment of Molecular Life Science, Basic Medical Science and Molecular Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Takashi ShiinaDepartment of Molecular Life Science, Basic Medical Science and Molecular Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Ichizo NishinoDepartment of Neuromuscular Research, National Institute of Neuroscience, and Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan.
Shigeaki SuzukiDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.
Tokai University · JPKeio University · JPNational Center of Neurology and Psychiatry · JPCharité - Universitätsmedizin Berlin · DEKumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInclusion body myositis (IBM) is an idiopathic inflammatory myopathy, characterized by unique clinical features including finger flexor and quadriceps muscle weakness and a lack of any reliable treatment. The human leukocyte antigen (HLA)-DRB1 allele and autoantibody profiles in Japanese IBM patients have not been fully elucidated.

methodsWe studied 83 Japanese IBM patients with a mean age of 69 years (49 males and 34 females) who participated in the 'Integrated Diagnosis Project for Inflammatory Myopathies' from January 2011 to September 2016. IBM was diagnosed by histological diagnosis. Various autoantibodies were screened by RNA immunoprecipitation and enzyme-linked immunosorbent assays. HLA-DRB1 genotyping was performed using polymerase chain reaction-sequence based typing. A total of 460 unrelated healthy Japanese controls were also studied.

resultsThe allele frequencies of DRB1*01:01, DRB1*04:10, and DRB1*15:02 were significantly higher in the IBM group than in the healthy control group (Corrected P = 0.00078, 0.00038 and 0.0046). There was a weak association between the DRB1*01:01 allele and severe leg muscle weakness and muscle atrophy. While hepatitis type C virus infection and autoantibodies to cytosolic 5'-nucleotidase 1A were found in 18 and 28 patients, respectively, no significant association with HLA-DRB1 alleles was observed.

conclusionJapanese IBM patients had the specific HLA-DRB1 allele and autoantibody profiles.

Indexed as

AllelesAgedAntibodies, ViralAsian PeopleAutoantibodiesFemaleGene FrequencyHepacivirusHLA-DRB1 ChainsHumansMaleMyositis, Inclusion BodyAntibodies, ViralAutoantibodiesHLA-DRB1 Chains

Identifiers

PMID32810190
PMCPMC7437458
OpenAlexW3052529750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.